Literature DB >> 33371795

LncRNA-Associated ceRNA Network Reveals Novel Potential Biomarkers of Laryngeal Squamous Cell Carcinoma.

Zhibin Jing1, Sitong Guo1, Peng Zhang1, Zheng Liang1.   

Abstract

OBJECTIVE: This study aims to construct a systematic mRNA-miRNA-lncRNA network to identify novel lncRNAs and miRNAs biomarkers for laryngeal squamous cell carcinoma (LSCC).
METHODS: The mRNA, miRNA and lncRNA expression profiles of LSCC were obtained from Gene Expression Omnibus (GEO) database. The differentially expressed mRNAs, miRNAs and lncRNAs (DEmRNAs, DEmiRNAs and DElncRNAs) were screened between LSCC tissues and controls. Functional analysis of DEmRNAs, DEmRNAs targeted by DEmiRNAs and DEmRNAs targeted by DElncRNAs were respectively performed. The miRWalk, starbase and DIANA-LncBase were respectively used to predict DEmiRNAs-DEmRNAs, DElncRNAs-DEmRNAs and DElncRNAs-DEmiRNAs pairs. ceRNA network was built by DEmiRNAs-DEmRNAs and DElncRNAs-DEmiRNAs pairs. LncRNA subcellular localization was predicted using lncLocator. Using published The Cancer Genome Atlas (TCGA) and external datasets (GSE127165 and GSE133632), we also validated the expression of key DElncRNAs and DEmiRNAs in ceRNA network. The diagnostic and prognostic value of candidate genes was evaluated by ROC curve analysis and survival analysis, respectively.
RESULTS: There were 5 mRNA datasets, 3 miRNA datasets and 2 lncRNA datasets in this study. Totally, 2957 DEmRNAs, 61 DElncRNAs and 23 DEmiRNAs were identified. Functional analysis of DEmRNAs shows that they were significantly enriched in cancer-related pathways, such as DNA replication and extracellular matrix organization. There were 11 DEmiRNAs, 17 DElncRNAs and 967 DEmRNAs in the ceRNA network. Notably, up-regulated lncRNA DGCR5-down-regulated has-miR-338-3p/has-miR-139-5p pairs in this network were experimentally validated. Moreover, down-regulated AL121839.2, down-regulated LINC02147, up-regulated AC079328.2, up-regulated AC004943.2 and up-regulated HMGA2-AS1 were located in the cytoplasm. AL121839.2 and LINC02147 interacted with has-miR-1246. AC004943.2, AC079328.2 and HMGA2-AS1 targeted has-miR-3185, has-miR-3137 and has-miR-582-5p, respectively. Based on the TCGA and external datasets (GSE127165 and GSE133632), DGCR5 and AC004943.2 were significantly up-regulated while AL121839.2 and LINC02147, has-miR-338-3p, has-miR-139-5p and has-miR-582-5p were significantly down-regulated, which were consistent with our integration analysis. DGCR5, AL121839.2, LINC02147, AC004943.2, has-miR-338-3p, has-miR-139-5p and has-miR-582-5p could predict the occurrence of LSCC. Survival analysis suggested that only, AL121839.2 has potential prognostic value for LSCC.
CONCLUSION: This study provided novel insights into the ceRNA network and uncovered novel lncRNAs and miRNAs with diagnostic value in LSCC.

Entities:  

Keywords:  competing endogenous RNA network; cytoplasm; laryngeal squamous cell carcinoma; long non-coding lncRNAs

Year:  2020        PMID: 33371795     DOI: 10.1177/1533033820985787

Source DB:  PubMed          Journal:  Technol Cancer Res Treat        ISSN: 1533-0338


  4 in total

1.  Circ_0044520 regulates the progression of laryngeal squamous cell carcinoma via the miR-338-3p/ROR2 axis.

Authors:  Huijun Yang; Gang Yu; Yan Wang; Xing Guo
Journal:  Histol Histopathol       Date:  2022-01-17       Impact factor: 2.130

2.  Upregulation of 15 Antisense Long Non-Coding RNAs in Osteosarcoma.

Authors:  Emel Rothzerg; Xuan Dung Ho; Jiake Xu; David Wood; Aare Märtson; Sulev Kõks
Journal:  Genes (Basel)       Date:  2021-07-26       Impact factor: 4.096

3.  The prognostic value and immune landscape of a cuproptosis-related lncRNA signature in head and neck squamous cell carcinoma.

Authors:  Yao Jun Li; Hai Yan Li; Quan Zhang; Sheng Li Wei
Journal:  Front Genet       Date:  2022-07-22       Impact factor: 4.772

Review 4.  A Review on the Role of miR-1246 in the Pathoetiology of Different Cancers.

Authors:  Soudeh Ghafouri-Fard; Tayyebeh Khoshbakht; Bashdar Mahmud Hussen; Mohammad Taheri; Mohammad Samadian
Journal:  Front Mol Biosci       Date:  2022-01-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.